Skip to content
ledwidge_pic_small

Affiliation

St Vincents University Healthcare Group, School of Medicine, University College, Dublin, Cardiology Department - Research Director, STOP-HF Unit

Country

Ireland

1. Current Status, Position

Mark Ledwidge is currently Research Director of the STOP-HF Unit in St Vincent’s University Healthcare Group, Dublin and UCD Professor (Adjunct) the School of Medicine, University College, Dublin.

2. Education

Mark studied pharmacy in Aberdeen, obtained a PhD in Pharmaceutics from Trinity College in 1997 and has worked as a pharmacist in community, hospital, industry and academia for almost 30 years.

3. Research Area

Major areas of interest include prevention of heart failure, heart failure therapeutics and pharmacogenomic strategies in heart failure. 

4. Conflict of interest

Prof. Mark Ledwidge is:
• Funder, Researcher of Abbott Diagnostics
• Co-founder of Solvatrin Therapeutics
• Funded Researcher for :
   • Novartis AG
   • Bayer
   • Hypercell

×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.